Dr. Ilaria is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
462 1st Ave
New York, NY 10016Phone+1 212-562-5555
Summary
- Dr. Robert Ilaria is an oncologist in Indianapolis, IN and is affiliated with multiple hospitals in the area, including Richard L. Roudebush Veterans Affairs Medical Center and NYC Health + Hospitals / Bellevue. He received his medical degree from University of Texas Southwestern Medical School and has been in practice 30 years. He specializes in hematologic oncology and sarcoma and is experienced in multiple myeloma, sarcomas, leukemia, and clinical drug development. He has more than 40 publications and over 500 citings.
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1990 - 1993- Brigham and Women's HospitalResidency, Internal Medicine, 1987 - 1990
University of Texas Southwestern Medical SchoolClass of 1987
Certifications & Licensure
NJ State Medical License Current
NY State Medical License 2019 - 2026
IN State Medical License 2005 - 2021
TX State Medical License 1999 - 2008
MA State Medical License 1989 - 2000- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 84 citationsThe CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia.Nicholas C. Wolff, James A. Richardson, Merrill J. Egorin, Robert L. Ilaria
Blood. 2003-06-15 - 106 citationsExpression of the EWS/FLI-1 oncogene in murine primary bone-derived cells Results in EWS/FLI-1-dependent, ewing sarcoma-like tumors.Yeny Castillero-Trejo, Susan Eliazer, Lilin Xiang, James A. Richardson, Robert Ilaria
Cancer Research. 2005-10-01 - 8 citationsRandomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.Oliver W. Hakenberg, Jose Luis Perez-Gracia, Daniel Castellano, Tomasz Demkow, Tarek Ali
European Journal of Cancer. 2019-01-01
Press Mentions
Infinity Pharmaceuticals to Be Featured in B. Riley Fireside ChatDecember 13th, 2021
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
